



TO: Pharmacies, Physicians, Nurse Practitioners, Physician Assistants, Long-Term Care Providers, Clinics, and Hospitals
RE: Wegovy Coverage for Metabolic-Associated Steatohepatitis (MASH) and new diagnosis Requirement for Wegovy for Major Adverse Cardiovascular Events (MACE)

Effective November 3, 2025, the Department will reimburse new prescriptions for Wegovy through the pharmacy benefit when prescribed to treat Metabolic-Associated Steatohepatitis (MASH) in adults 18 and older. This prescription will be reimbursed under the HUSKY Health Programs (A, C, and D) for those meeting the specified criteria.

Established Metabolic-Associated Steatohepatitis (MASH) includes presenting a medical history of the following:

- histologically documented steatohepatitis
- NAFLD Fibrosis Score (NFS) greater than or equal to 4
- A hepatic decompensation or Model for End-Stage Liver Disease (MELD) score of less than or equal to 12 points
- AST and ALT levels are less than or equal to 5 times upper limit of normal.

Wegovy will **NOT** be covered:

- Exclusively for weight management, or
- Type 1 or Type 2 diabetes

The prescriber is required to complete and submit a prior authorization (PA) request form for Wegovy for members meeting the criteria above for a diagnosis indicating MASH each time new therapy is requested and annually thereafter.

There will be a **new** prior authorization form available to providers on November 3, 2025, and will be found at www.ctdssmap.com under the Pharmacy Program Publications

panel. The PA form titled, 'Wegovy for MASH Prior Authorization Form', will detail criteria necessary for coverage. The existing Prior Authorization Form (WEGOVY for MACE (Major Adverse Cardiovascular Events)), will continue to be available for those clients meeting the existing criteria for the treatment of MACE as documented on the Form.

The prescriber is advised that specific information is required to be submitted on the PA form. Any PA form submitted without the required information will be denied.

Effective November 3, 2025, all Wegovy prescriptions will require a diagnosis code. Only diagnosis codes that indicate an established major adverse cardiovascular event or for established MASH will be payable. The diagnosis code requirement is in addition to the prior authorization requirement. The list of payable diagnosis codes for Wegovy will be available on www.ctdssmap.com → Pharmacy → ICD-10-CM-Therapeutic Class Product Diagnosis List